Ovoca Bio Plc Logo

Ovoca Bio Plc

Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).

OVXA | IR

Overview

Corporate Details

ISIN(s):
IE0006649010 (+1 more)
LEI:
213800ST2AK5XQ1O5207
Country:
Ireland
Address:
17 PEMBROKE STREET UPPER, D02 AT22 DUBLIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ovoca Bio Plc is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. The company's lead product candidate is Orenetide, a medicinal therapy for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition with significant unmet medical need. Ovoca Bio is advancing Orenetide through clinical development and regulatory approval processes in the US, Europe, and other major global markets. The company's strategy involves leveraging its protective patent portfolio and seeking commercialization through licensing agreements and collaborations with pharmaceutical partners.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 14:09
Report Publication Announcement
Replacement Half Year Report
English 10.8 KB
2025-06-05 08:00
Delisting Announcement
Delisting from Euronext Growth Exchange
English 9.0 KB
2025-03-03 15:00
Board/Management Information
Management Changes
English 8.0 KB
2024-12-18 19:00
Post-Annual General Meeting Information
Result of AGM
English 7.1 KB
2024-11-18 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 7.0 KB
2024-10-11 18:30
Major Shareholding Notification
Holding(s) in Company
English 6.8 KB
2024-10-09 18:45
Transaction in Own Shares
Sale of Treasury Shares
English 6.0 KB
2024-09-25 08:00
Report Publication Announcement
Half-year Report
English 7.6 KB
2024-09-02 15:30
Related Party Transaction
Consultancy Agreement
English 8.7 KB
2024-07-15 08:00
Director's Dealing
Director/PDMR Shareholding
English 27.4 KB
2024-07-15 08:00
Board/Management Information
Directorate Change
English 8.8 KB
2024-06-28 08:00
Report Publication Announcement
Annual Financial Report
English 14.5 KB
2024-06-20 00:00
Annual Report
English 1.2 MB
2024-01-23 08:00
Major Shareholding Notification
Holding(s) in Company
English 7.9 KB
2023-12-01 13:00
Post-Annual General Meeting Information
Result of AGM
English 7.8 KB

Automate Your Workflow. Get a real-time feed of all Ovoca Bio Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ovoca Bio Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ovoca Bio Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.